The University of Texas at Arlington
Trial Pipeline
Virtual Reality Lethal Means Safety Training
NCT07219355
Using Near-Infrared Light to Better Understand Peripheral Artery Disease
NCT07313410
Asthma Intervention With Residential Ventilation and Air Cleaner (AIRVAC) Study
NCT07196436
Arlington Aging Study
NCT06857877
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring
NCT06150989
Reducing Blood Pressure in Mid-life Adult Binge Drinkers
NCT05522075
Exploring Virtual Reality Adventure Training Exergaming
NCT05563805
Virtual Reality-Infused Treadmill Training on Aging-Related Outcomes
NCT06727942
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
NCT03471117
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
NCT03982160
Brain Vascular and Neurocognitive Health
NCT06497413
Partnership in Resilience for Medication Safety (PROMIS)
NCT05880368
Effect of Waterpipe Size on Smoking Behavior and Exposures
NCT05705375
The Senior Companion Program Plus
NCT03602391
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 2 |
What the Pipeline for The University of Texas at Arlington Shows
According to the ClinicalTrials.gov registry, The University of Texas at Arlington is linked to 73 US clinical trials across every stage of research activity. Of those, 69 studies are currently recruiting — about 95% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 5% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for The University of Texas at Arlington reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for The University of Texas at Arlington is Aging with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.